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Allele and dosage specificity of the Peg3
imprinted domain
Corey L. Bretz, Wesley D. Frey, Ryoichi Teruyama, Joomyeong Kim*
Department of Biological Sciences, Louisiana State University, Baton Rouge, LA, United States of America
* jkim@lsu.edu
Abstract
The biological impetus for gene dosage and allele specificity of mammalian imprinted genes
is not fully understood. To address this, we generated and analyzed four sets of mice from
a single breeding scheme with varying allelic expression and gene dosage of the Peg3
domain. The mutants with abrogation of the two paternally expressed genes, Peg3 and
Usp29, showed a significant decrease in growth rates for both males and females, while the
mutants with biallelic expression of Peg3 and Usp29 resulted in an increased growth rate of
female mice only. The mutant cohort with biallelic expression of Peg3 and Usp29 tended to
have greater numbers of pups compared to the other genotypes. The mutants with switched
active alleles displayed overall similar phenotypes to the wild type, but did show some differ-
ences in gene expression, suggesting potential non-redundant roles contributed by the
maternal and paternal alleles. Overall, this study demonstrates a novel in vivo approach to
investigate the allele and dosage specificity of mammalian imprinted domains.
Introduction
In placental mammals, the majority of autosomal genes have two functional copies, which are
contributed by two parents. In contrast, a very small subset of genes has only one functional
copy due to genomic imprinting, by which one allele is inactivated by epigenetic mechanisms
[1–3]. This mono-allelic expression or single gene dosage driven by genomic imprinting has
been functionally selected and preserved during the evolution of eutherian mammals [1–3].
Each imprinted gene is also expressed from one specified allele, either the maternally or pater-
nally inherited copy, and this allele specificity is well conserved among all the eutherian mam-
mals. About 100 to 200 genes are imprinted in mammalian genomes, and these genes are
usually expressed in early-stage embryo, placenta and brain [1–3]. Mutations in these
imprinted genes have very similar functional outcomes, such as changes in fetal growth rates
and perturbations in animal nurturing behaviors. Yet, genomic imprinting is found only
within the eutherian lineage that has a very unusual reproduction strategy involving viviparity
and placentation. Thus, genomic imprinting is thought to have co-evolved with the reproduc-
tion scheme of placental mammals to control the dosage of the genes that play critical roles in
the reproduction-related physiology and behaviors [4–7]. Nevertheless, the actual biological
reasons for the allele and dosage specificity associated with each imprinted gene have not been
well understood so far.
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Peg3 (Paternally expressed gene 3) is the founding member of the 500-kb imprinted domain
localized in human chromosome 19q13.4/proximal mouse chromosome 7 [8–10]. This
domain contains paternally expressed Peg3, Usp29, Zfp264, APeg3 and maternally expressed
Zim1, Zim2, Zim3 [11]. As described earlier, the allele and dosage specificity of the Peg3
domain are well conserved among all the placental mammals. The functions of these genes are
also closely associated with controlling fetal growth rates and nurturing behaviors [12–15].
The imprinting of this domain is controlled through an ICR (Imprinting Control Region), the
Peg3-DMR (Differentially Methylated Region), which encompasses the bidirectional promoter
for Peg3/Usp29 [16, 17]. Deletion of this ICR abolishes the transcription of Peg3 and Usp29,
and also causes biallelic expression, or double dosage for some of the adjacent imprinted genes
[18]. In particular, the maternally expressed Zim1 becomes biallelic due to the reactivation of
the paternal allele. The Peg3-DMR obtains its gametic DNA methylation during oogenesis,
which is then maintained in somatic cells throughout the lifetime of the animal [18, 19].
Recent studies further revealed that one upstream alternative promoter, termed U1, is respon-
sible for establishing this oocyte-specific DNA methylation on the Peg3-DMR [20]. Deletion
of this alternative promoter results in a loss of the allele-specific methylation on the
Peg3-DMR, subsequently causing biallelic expression or double dosage of Peg3 and Usp29.
In the current study, we sought to characterize the allele and dosage specificity associated
with the Peg3 domain by using two mutant alleles that target the Peg3-DMR and the alterna-
tive U1 promoter. According to the results, the gene dosage of the Peg3 domain is indeed
closely associated with the growth rates of the animals. Also, although the allele switching of
the Peg3 domain did not cause any major impact on animal growth, detailed examinations
suggest the presence of potential differences in gene expression between the two alleles.
Results
Generation of four genotypes with different dosage and allele specificity
In the current study, we used two deletion alleles to generate the mutant pups with different
dosage and allele specificity. The first mutant allele termed KO2 is deigned to delete the
Peg3-DMR, a 4-kb genomic region encompassing the bidirectional promoter for the two
paternally expressed genes, Peg3 and Usp29 (Fig 1B). Paternal deletion of this 4-kb region
abolishes the expression of Peg3 and Usp29, and also causes reactivation of the maternally
expressed Zim1 from the paternal allele [17]. The second mutant allele termed U1ΔR is
designed to delete the 1-kb genomic region encompassing the alternative U1 promoter, which
is located 20-kb upstream of the Peg3-DMR (Fig 1A). The transcription driven by this alterna-
tive promoter during oogenesis is responsible for oocyte-specific DNA methylation on the
Peg3-DMR. Thus, maternal deletion of the U1 promoter results in the loss of oocyte-driven
DNA methylation on the Peg3-DMR, and subsequent reactivation of the two paternally
expressed genes, Peg3 and Usp29, from the maternal allele (Fig 1C). As a consequence, the
expression of Zim1 is also significantly down-regulated to its basal levels from the maternal
allele, exhibiting about 3 to 5% of the normal expression levels [20].
As a breeding scheme, we crossed 10 females that were heterozygous for the U1ΔR allele
with 5 males that were heterozygous for the KO2 allele (Fig 2A). This breeding scheme with
the two sets of heterozygotes was designed to derive the following four groups of pups with dif-
ferent genotypes (Fig 2B). The first group is the pups with two wild-type alleles, displaying
normal allele and dosage specificity. In this genotype, referred to as simply ’WT’ hereafter,
Peg3 and Usp29 are expressed from the paternal allele whereas Zim1 is expressed from the
maternal allele (Fig 2C). The second group is the pups with the paternal transmission of the
KO2 allele. In this genotype, referred to as ’KO2’, the expression of Peg3 and Usp29 is
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abolished, and the expression of Zim1 becomes biallelic due to the reactivation of the paternal
Zim1. The third group is the pups with the maternal transmission of the U1ΔR allele. In this
genotype, referred to as ’U1’, the expression of Peg3 and Usp29 becomes biallelic due to the
reactivation of the maternal allele, and also significant down-regulation of the maternal Zim1.
Fig 1. Schematic representation of the mouse Peg3 domain and two mutant alleles. (A) Mouse Peg3 imprinted
domain. The 500-kb imprinted domain contains 7 genes, which are indicated by arrows. Paternally expressed Peg3,
Usp29, Zfp264,APeg3 are indicated by the corresponding gene names with blue font, whereas the maternally expressed
Zim1, Zim2, Zim3 are indicated by the corresponding gene names with red font. The 4-kb Peg3-DMR controls the
imprinting of the entire domain, which is indicated by a grey box (nucleotide positions 6,718,442–6,733,840 in the
mouse chromosome 7 of mm10). In contrast, the alternative U1 promoter is known to target de novo DNA
methylation to the maternal allele of the Peg3-DMR. This alternative promoter is localized 20-kb upstream of the
Peg3-DMR, indicated with a small arrow (nucleotide positions 6,750,937–6,751,933 in the mouse chromosome 7 of
mm10). (B) Deletion of the paternal allele of the Peg3-DMR abolishes the transcription of two paternally expressed
genes, Peg3 and Usp29, and consequently causes the reactivation of the paternal Zim1. (C) Deletion of the U1 promoter
during oogenesis results in the reactivation of two paternally expressed genes, Peg3 and Usp29, from the maternal
allele, and subsequently causes significant down-regulation of the maternal Zim1.
https://doi.org/10.1371/journal.pone.0197069.g001
Fig 2. Breeding scheme and the allele and dosage specificity of the subsequent progeny. (A) Schematic
representation of two deletion mutants for the breeding. The females carry the deletion allele for the alternative U1
promoter (U1ΔR), whereas the males carry the deletion allele for the Peg3-DMR (KO2). (B) The intercrossing of these
two mutants produces the pups with 4 different genotypes: WT/WT, WT/KO2, U1ΔR/WT, U1ΔR/KO2. (C) Given the
known effects by two mutant alleles, each genotype is predicted to have different dosage and allele specificity for the
genes of the Peg3 domain. These predicted outcomes are summarized in the following manner. The 1 X indicates the
expression from a single allele, whereas the 2 X indicates the expression from two alleles. The genes with red font
indicate the expression from the maternal allele, whereas those with blue font indicate the expression from the paternal
allele. The genes with black indicate biallelic expression. The genes with strike-through indicate the significant down-
regulation or no expression from that particular allele.
https://doi.org/10.1371/journal.pone.0197069.g002
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Finally, the fourth group is the pups with the maternal and paternal transmission of U1ΔR and
KO2, respectively. In this genotype, referred to as ’U1/KO2’, Peg3 and Usp29 are expressed
from the maternal allele, while Zim1 is expressed from the paternal allele. We performed this
series of breeding experiments, which successfully generated a total of 18 litters of pups with
all of the predicted genotypes.
DNA methylation of the Peg3 domain among the four genotypes
The generated pups were analyzed in terms of their DNA methylation levels (Fig 3). This series
of analyses used the DNA that had been isolated from the tails of the female and male sets. The
isolated DNA were first genotyped with the primer sets targeting two deleted regions, the 1-kb
genomic region harboring U1 and the 4-kb genomic region covering the Peg3-DMR (Fig 3B).
The DNA were later treated with the bisulfite conversion protocol [21], which were then used
for amplifying the following four target regions: Peg3-DMR, the promoter of Zim1, Zim2-
DMR, and Zfp264-DMR (Fig 3A). The amplified DNA were subsequently analyzed with the
COBRA (COmbined Bisulfite Restriction Analysis) protocol [22]. As shown in Fig 3C, the
DMRs of the Peg3 and Zfp264 displayed about 50% DNA methylation levels in the WT samples
(lane 1 and 5), while the promoter of Zim1 did not show any levels of DNA methylation. In the
case of the KO2 samples (lane 2 and 6), the Peg3-DMR showed a complete methylation pat-
tern. This agrees with the fact that the amplified products were derived only from the
Fig 3. DNA methylation status of the Peg3 domain among the four genotypes. (A) The positions of three DMRs are
indicated on the genomic map of the Peg3 domain. (B) The genotypes of the female and male sets of the pups are
presented along with the results derived from the two sets of PCR amplifying the deleted regions. (C) The DNA from
the four genotypes of both sexes were treated with bisulfite conversion protocol for DNA methylation analyses. The
DNA were then amplified with four primer sets targeting the Peg3-DMR, the promoter of Zim1, Zim2-DMR and the
Zfp264-DMR. The amplified products were digested with individual restriction enzymes that can differentiate the CpG
methylation status of the original DNA, which are indicated with (U)nmethylation and (M)ethylation for a given CpG
site.
https://doi.org/10.1371/journal.pone.0197069.g003
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methylated maternal allele, but not from the paternal allele due to the deletion of the entire
4-kb Peg3-DMR. In the case of the U1 samples (lane 3 and 7), the maternal allele of the
Peg3-DMR was inherited as an unmethylated allele similar to the paternal allele, thus showing
a complete unmethylation pattern. In the case of the U1/KO2 samples (lane 4 and 8), the
remaining maternal allele of the Peg3-DMR showed a complete unmethylation pattern, which
agrees with the fact that the U1 deletion causes a loss of DNA methylation on the remaining
maternal allele. On the other hand, the DNA methylation patterns of the other DMRs and the
promoter of Zim1 were not affected at all by the two deletions. This is consistent with the pre-
vious observations from the two studies analyzing KO2 and U1 mutants individually [17, 20].
Taken together, this series of DNA methylation analyses confirmed that the generated pups
with the four genotypes maintain the DNA methylation pattern as predicted.
Expression levels of the imprinted genes in the four genotypes
The generated pups were analyzed in terms of their expression levels of the individual genes
within the Peg3 domain. For this series of analyses, we isolated total RNA from the female
(n = 3) and male (n = 3) sets of one-day-old neonatal heads representing the four genotypes
(Fig 4). The isolated RNA was converted into cDNA, and subsequently used as templates for
qRT-PCR analyses. This series of expression analyses focused mainly on the following four
genes for the Peg3 domain: Peg3, Usp29, Zim1 and Zfp264. The other remaining genes, Zim2,
Zim3 and APeg3, were omitted due to their low expression levels in neonatal heads (Fig 1A).
The results are summarized as follows. First, the KO2 samples showed no detectable levels of
expression for both Peg3 and Usp29 (p = 0.0004, Mann-Whitney U test), yet exhibited a 2-fold
up-regulation of Zim1 (p = 0.0004, Mann-Whitney U test) compared to the levels observed
from the WT samples (red bars in Fig 4). This was expected since the deletion of the
Fig 4. Expression levels of the Peg3 domain and the gene set for lipid metabolism among the four genotypes. A
series of qRT-PCR-based analyses were performed using three sets of total RNA isolated from the neonatal heads of the
four genotypes of females (A) and males (B). The expression levels of the imprinted genes of the Peg3 domain were
summarized on the graph on left, whereas the expression levels of the gene set for lipid metabolism on the graph on
right. The expression levels of each gene were first normalized with an internal control (β-actin). The subsequent value
was further compared to that of the WT sample, which has been indicated with dotted lines. The relative levels were
presented with standards deviation. Statistically significant differences in expression have been indicated with  being
less than 0.05 and  being less than 0.001. The corresponding p values were also pointed out in the text. This set of
analyses was repeated using three biological replicates.
https://doi.org/10.1371/journal.pone.0197069.g004
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Peg3-DMR in the KO2 samples abolishes the bidirectional promoter for Peg3/Usp29. The up-
regulation of Zim1 also has been observed from the various mutants targeting the Peg3 locus
[16, 17, 20], but the exact 2-fold up-regulation of Zim1 appeared to be very precise given the
predicted double gene dosage in the KO2 sample (Fig 2C). The overall expression patterns of
genes in the Peg3 domain from the KO2 samples were also similar between two sexes. Second,
the U1 samples displayed 2-fold up-regulation for both Peg3 and Usp29 (p = 0.0004 and 0.0061
respectively, Mann-Whitney U test), and also significant down-regulation of Zim1 (p = 0.0004,
Mann-Whitney U test) to basal levels (green bars in Fig 4). The 2-fold up-regulation of Peg3
and Usp29 was consistent with the predicted double gene dosage for both genes, which was
presumably caused by the reactivation of the maternal allele by the U1 deletion. The overall
expression patterns of genes in the Peg3 domain from the U1 samples were also similar
between two sexes. Third, the U1/KO2 samples displayed similar levels of expression for the
four genes as compared to those observed from the WT samples (purple bars in Fig 4). This
suggests that the reactivated maternal allele of the Peg3-DMR via the U1 deletion may have
rescued the abnormal expression patterns of the Peg3 domain, which had been caused by the
paternal deletion of the Peg3-DMR. It is, however, interesting to note that the expression levels
of the Peg3 domain were slightly different between WT and U1/KO2. Overall, this series of
expression analyses confirmed that the predicted gene dosages of the individual genes were
indeed manifested as the corresponding expression level differences between the individual
genotypes.
Expression levels of the other genes associated with Peg3 in the four
genotypes
We also tested the expression levels of several genes that are known to be closely associated
with the gene dosage of Peg3. In particular, mutations in Peg3 are known to affect the tran-
scription levels of the two particular gene sets: the genes involved in lipid metabolism and sev-
eral genes highly expressed in the hypothalamus [14]. Thus, we analyzed the expression levels
of these genes using male (n = 3) and female (n = 3) cDNA sets derived from the four geno-
types. First, we measured the expression levels of the following genes for lipid metabolism:
Pparg, Cidea, Cidec, Fabp4, Plin4, Cfd and Adig (Fig 4). According to the results, the U1 sam-
ples showed the most significant changes in the expression levels of this gene set among the
four genotypes. Yet, the changes were opposite between the two sexes. In the case of females,
the expression levels of two genes, Pparg and Fabp4, were both 1.5-fold up-regulated compared
to those of the wild type (p = 0.0004 for Pparg and p = 0.0025 for Fabp4, Mann-Whitney U
test). In the case of males, the U1 samples showed significant down-regulation of all the genes
for lipid metabolism, ranging from 3% to 47% levels of the WT sample (p = 0.0004 for all of
the genes, Mann-Whitney U test). On the other hand, the other two groups, KO2 and U1/
KO2, showed no major change with similar levels to those observed from WT. Besides the U1
samples, we also observed consistent down-regulation of this gene set from the female samples
of the U1/KO2 genotype (p = 0.072 for Pparg and p = 0.0004 for the remainders, Mann-Whit-
ney U test). This change ranged from 26 to 87% level of the WT sample (purple bars), suggest-
ing potential effects by switching the active alleles of the Peg3 domain.
We also performed a similar series of expression analyses for the following genes: Oxtr,
Avp, Oxt, Peg10 and Msl1 (Fig 5). The three genes (Oxtr, Oxt and Avp) and Peg3 have been
shown to be involved in maternal-caring behaviors and controlling the volume of bodily fluids
[23, 24], while Msl1 and Peg10 are known to be downstream targets of Peg3 [25–27]. For this
series of expression analyses, we used male (n = 3) and female (n = 3) cDNA sets that had been
generated using the total RNA from neonatal heads and adult hypothalamus. According to the
Allele and dosage specificity of Peg3
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results, the expression levels of these genes were overall similar among the four genotypes
except that the levels of Oxt were 2.0-fold up-regulated in both males and females of the KO2
samples (p = 0.0004 Mann-Whitney U test) (Fig 5A). This initial observation was further sup-
ported by the results from the cDNA of adult hypothalamus, showing 2 to 2.5-fold up-regula-
tion of Oxt in both male and female samples (p = 0.0004 for male and p = 0.0005 for female,
Mann-Whitney U test) (Fig 5C and Fig 5D). Besides Oxt, we also observed up-regulation of
Avp in adult females (p = 0.0004, Mann-Whitney U test) and males (0.0023 Mann-Whitney U
test). Overall, this series of analyses concluded that the gene set for lipid metabolism was up
and down-regulated in the female and male of the U1 genotype, respectively, and also that the
expression levels of Oxt were up-regulated in the KO2 sample.
Spatial expression patterns of Peg3 and Oxt in the four genotypes
We performed a series of immunostaining to monitor the spatial expression pattern of Peg3
and also to further confirm the observed up-regulation of Oxt (Fig 6). For this series of immu-
nostaining, we harvested a set of 8 hypothalamus samples from 3-month-old adult mice, repre-
senting the four genotypes of both sexes. This set of hypothalamus samples were sectioned to
derive coronal slices with 40 μm thickness, which were subsequently used for the double stain-
ing with two antibodies: anti-PEG3 and anti-OXT antibodies. The results are summarized as
follows. First, we observed the immunoreactivity with anti-PEG3 antibody from the sectioned
slices of the three genotypes, WT, U1, U1/KO2 (green dots), but not from those of the KO2
genotype. This agrees with the expression of Peg3 within the hypothalamus of the three geno-
types, WT, U1, U1/KO2, and also with no expression of Peg3 in the KO2 sample (Fig 5C and
Fig 5D). The signals were somewhat stronger in the U1 sample than the other two genotypes,
WT and U1/KO2. This is also consistent with the fact that the expression levels in the U1 were
2-fold higher than those from the other two genotypes (Fig 5C and Fig 5D). Second, we
Fig 5. Expression levels of the Peg3-associated genes among the four genotypes. A series of qRT-PCR-based
analyses were performed using the total RNA isolated from the neonatal heads of females (A) and males (B), and also
from the adult hypothalamus of females (C) and males (D) of the four genotypes. The expression levels of each gene
were first normalized with an internal control (β-actin). The subsequent value was further compared to that of the WT
sample, which has been indicated with dotted lines. The relative levels were presented with standards deviation.
Statistically significant differences in expression have been indicated with  being less than 0.05 and  being less than
0.001. The corresponding p values were also pointed out in the text. This set of analyses was repeated using three
biological replicates for the neonatal set and two biological replicates for the adult hypothalamus.
https://doi.org/10.1371/journal.pone.0197069.g005
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observed the immunoreactivity with anti-OXT antibody from the four genotypes, mainly from
the PVN (Paraventricular nucleus) and SON (Supraoptic nucleus) areas (red dots in Fig 6).
We further counted the number of neuronal cells that were immunoreactive with the anti-
OXT antibody using the entire set of sectioned slices, about 70 slices per each genotype. The
total numbers of the positive neuronal cells were 2376 for WT, 3217 for KO2, 2794 for U1,
3627 for U1/KO2. The relatively high number from the KO2 sample also agrees with the up-
regulation of Oxt observed from KO2 through qRT-PCR analyses (Fig 5C and Fig 5D). The
observations described above were derived from the male set of the hypothalamus. Overall,
this series of immunostaining confirmed the similar spatial expression pattern of Peg3 among
the three genotypes, WT, U1, U1/KO2, and also detailed the up-regulation of Oxt in the adult
hypothalamus of the KO2 genotype.
Survival and growth rates of the four genotypes
We also analyzed the generated pups in terms of their survival and growth rates (Fig 7). For
this series of analyses, the pups were sexed and genotyped, and also their weights were mea-
sured at either birth (postnatal day 1) or weaning ages (postnatal day 21). The results are sum-
marized as follows. First, the intercrossing between two heterozygotes, females with the
maternal deletion of the U1 promoter and males with the paternal deletion of the Peg3-DMR
(Fig 2A), derived a total of 158 pups for 18 litters with the average litter size being 8.72. This lit-
ter size is considered to be normal for the mouse of the C57BL/6J background, thus no embry-
onic lethality is thought to be associated with this breeding scheme, especially after the
implantation stage. Out of the 158 pups, 13 pups died within a couple of days after their birth,
but with no clear association to any genotype (S1 File). These 158 pups were further divided
Fig 6. Spatial expression patterns of Peg3 and Oxt within the adult hypothalamus. Double staining of PEG3 (green)
and OXT (red) immunoreactive neurons in the hypothalamus of 3-month-old mice of the four genotypes (A-D).
PEG3 immunoreactive neuronal cells were detected throughout the entire area of the hypothalamus of the three
genotypes (WT, U1, U1/KO2), whereas OXT immunoreactive neurons were mainly detected from the PVN
(Paraventicular nucleus) and SON (Supraoptic nucleus) areas of the hypothalamus.
https://doi.org/10.1371/journal.pone.0197069.g006
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into the four genotypes in the following manner: 32 pups (15 Females + 17 Males) for WT; 37
pups (20 Females + 17 Males) for KO2; 53 pups (22 Females + 31 Males) for U1; and 36 pups
(21 Females + 15 Males) for U1/KO2 (Fig 7A). Given the observed frequencies, the U1 geno-
type appeared to have the highest number of pups among the four genotypes, although statisti-
cally not significant (p = 0.08, chi-square test). Thus, this suggests that the double gene dosage
of Peg3 and Usp29 might provide U1 mutants a competitive advantage. It is also interesting to
note that males tend to be over-represented in the U1 group (22 Females + 31 Males), which is
consistent with the previous study that females were under-represented among the mutants
with the double dosage of Peg3 and Usp29 [20]. Second, the weight profiles revealed that the
KO2 genotype showed significant reduction (p< 0.0001, student’s t-test) in their body weights
in both sexes (Fig 7B and Fig 7C and S1 File), which agrees with the previous studies [12–15].
The weight profiles also revealed two unique observations. In the case of the U1 genotype, the
double dosage of Peg3 and Usp29 seemed to have a major effect on the growth rate of the female
pups based on the average weight difference between U1 (108%) and WT (98%) (p = 0.004, stu-
dent’s t-test). This difference, however, was not detected in the males (110% in both U1 and
WT genotypes, p = 0.42, student’s t-test). Thus, the double dosage of Peg3 and Usp29 and/or
reduction of Zim1 appeared to result in increased growth rates only in the female pups. In the
case of the U1/KO2 genotype, the weight of females became heavier than that of WT (103% ver-
sus 98%), whereas the weight of the males became lighter than that of WT (105% versus 110%).
However, neither were statistically significant from WT (p = 0.077 for females and p = 0.2 for
males, student’s t-test). In conclusion, this series of breeding experiments provided two main
observations: 1) the U1 genotype may have a competitive advantage and 2) the growth rate of
KO2 mice was drastically reduced while the growth rate of U1 female mice was increased.
Discussion
In the current study, we characterized the allele and dosage specificity associated with the Peg3
domain by using two mutant alleles targeting the Peg3-DMR and the alternative U1 promoter.
Fig 7. Summary of breeding experiments. A total of 158 pups derived from the breeding were summarized based on
the transmission frequency of each mutant allele (A), the average weight (B), and also the weight profile of individual
pups (C). Each pup was measured at the birth and weaning ages, which was then further divided with the average
weight of the litter. The subsequent value (%) was used for calculating the average weight for each genotype (B) and
also the individual weight profile (C).
https://doi.org/10.1371/journal.pone.0197069.g007
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According to the results, the mutants with abrogation of Peg3 and Usp29 expression showed
drastic reductions in growth rates for both male and female mice. In contrast, the mutant
group with double dosage of Peg3 and Usp29 displayed an increase in growth rate of female
mice. The mutant with switched active alleles did not cause any major impact on animal
growth and survival, but displayed some differences in gene expression compared to wild type.
Overall, the gene dosage of the Peg3 domain is closely associated with the growth rates of the
animals.
The mutant with double dosage of Peg3 and Usp29 appeared to be the fittest among the four
genotypes based on the highest survival rates and growth rates (Fig 7). Nevertheless, the Peg3
domain has been maintained as a single-dosage imprinted domain throughout mammalian
evolution [11], suggesting the presence of some unknown functional constraints hindering the
evolutionary selection of the animals with double dosage of Peg3 and Usp29. The Peg3 domain
has been shown to be sexually biased according to previous studies [17, 28, 29]. The expression
levels of the Peg3 domain are higher in males than in females, and also mutations on this locus
tend to have different effects between two sexes. The current study also provides a similar
observation that the mutant group with the double dosage of Peg3 and Usp29 was somewhat
over-represented by males (Fig 7A), which is consistent with the results from the previous
study [20]. Thus, it is feasible to predict that different optimum gene dosages between two
sexes might be a potential constraint maintaining the imprinting of the Peg3 domain, which
might be interesting to pursue in the near future.
The gene dosage of the Peg3 domain appeared to be closely associated with the expression
levels of the gene set involved in lipid metabolism (Fig 4). This is also consistent with the
results from the previous studies demonstrating that loss-of-function type mutations in Peg3
tend to result in smaller body sizes but with higher percentages of adipocytes, and also that
lipid metabolism is one of the biological pathways that are affected in the mutants targeting
Peg3 [13, 14]. According to the results from the current study, however, the increased dosage
of Peg3/Usp29 resulted in two opposite outcomes between sexes: the gene set for lipid metabo-
lism was significantly down-regulated in males whereas up-regulated in females (Fig 4). This
is further supported by the female mutants with double dosage of Peg3/Usp29, which showed
the highest growth rates among the four genotypes (Fig 7). The increased growth rates were
also more pronounced prior to weaning, when the main diet is fat-rich milk for the pups. Dur-
ing the postnatal stage, the milk may be converted into the fat depots of this mutant more effi-
ciently than the other three genotypes, since the females of this mutant have already elevated
expression levels of the gene set for lipid metabolism (Fig 4). As an imprinted gene, Peg3’s
close association with lipid metabolism also agrees with the idea that genomic imprinting may
have been implemented to provide placental mammals the genetic means by which females
can provide fat-rich milk to the offspring [4–7]. Overall, lipid metabolism appears to be one of
the most responsive pathways that are affected by the increased gene dosage of the Peg3
domain.
The mutant with switched active alleles (U1/KO2) displayed overall similar but slightly dif-
ferent phenotypic outcomes from the wild type. The observed differences include slightly dif-
ferent expression levels of the Peg3 domain and different body weights compared to the wild
type (Fig 4 and Fig 7). These observed differences might be an indication that the two alleles
of the Peg3 domain may still be different from each other regardless allelic-specific DNA meth-
ylation on the Peg3-DMR. One feasible explanation would be that some unknown enhancers
might be allele-specific. In that regard, it is relevant to note that the Peg3 domain contains the
200-kb genomic region that harbors about 20 evolutionarily conserved regions (ECRs) [30,
31]. Some of these putative enhancers might be paternal-specific and responsible for the spatial
and temporal expression patterns of the paternally expressed Peg3 and Usp29. The other group
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of enhancers might be maternal-specific and control the expression pattern of the maternally
expressed Zim1. In this situation, switching alleles might put the promoters of individual genes
under a different set of enhancers, causing slightly different expression levels and patterns for
the associated imprinted genes. If this is indeed the case, this would have the following implica-
tions. First, genomic imprinting may be regulated not only through ICRs but also through
allele-specific enhancers. Second, it is likely that the reactivated imprinted allele for a given
domain may not be biologically equivalent to the opposite active allele, which normally pro-
duces functional gene products. This further implicates that reactivating the repressed alleles
for human imprinting disorders, such as Prader-Willi/Angelman syndromes, may not com-
pensate completely for the loss of the corresponding active alleles [32, 33]. Overall, investigat-




All the experiments related to mice were performed in accordance with National Institutes of
Health guidelines for care and use of animals, and also approved by the Louisiana State Uni-
versity Institutional Animal Care and Use Committee (IACUC), protocol #16–060.
Mouse breeding
In the current study, we used two mutant strains that have been previously characterized: the
KO2 strain with the 4-kb deletion of the Peg3-DMR and the U1ΔR strain with the 1-kb dele-
tion of the alternative U1 promoter [17, 20]. Ten female heterozygotes for the U1ΔR allele
were crossed with five male heterozygotes for the KO2 allele. The subsequent pups were ana-
lyzed in terms of sex, genotype and weight. Statistical significance of potential difference in the
sex ratio, allele frequency and average weight between the genotypes was assessed using chi-
squared test. For genotyping, genomic DNA was isolated from either clipped ears or tail snips
by incubating the tissues overnight at 55˚C in the lysis buffer (0.1 M Tris-Cl, pH 8.8, 5 mM
EDTA, pH 8.0, 0.2% SDS, 0.2 M NaCl, 20 μg/ml Proteinase K). The isolated DNA was subse-
quently genotyped using the following two sets of primers: for the KO2 allele, Primer A (5’-
TGACAAGTGGGCTTGCTGCAG-3’), B (5’-GGATGTAAGATGGAGGCACTGT-3’), and D
(5’-AGGGGAGAACAGACTACAGA-3’); for the U1ΔR allele, P1 (5’-TAGCAAGGGAGAG
GGCCTAG-3’), P2 (5’-GGAAGCCTCCATCCGTTTGT-3’), and P3 (5’-AGCACAGCTAGAA
ATACACAGA-3’). The sex of the pups was determined through PCR using the following
primer set: mSry-F (5’-GTCCCGTGGTGAGAGGCACAAG-3’) and mSry-R (5’-GCAGCTCT
ACTCCAGTCTTGCC-3’).
DNA methylation analysis
For DNA methylation analyses, the genomic DNA isolated from tail snips were treated with
the bisulfite conversion reaction according to the manufacturer’s protocol (EZ DNA methyla-
tion kit, Zymo Research) [21]. The converted DNA was used as a template for the PCR reac-
tion using the primer set that was designed for amplifying each target region. The amplified
products were analyzed with COBRA (COmbined Bisulfite and Restriction Analysis) [22]. The
information regarding the sequences of oligonucleotides and the PCR conditions for each
genomic region is also available through the previous study [17].
Allele and dosage specificity of Peg3
PLOS ONE | https://doi.org/10.1371/journal.pone.0197069 May 7, 2018 11 / 14
Expression analyses
Total RNA was isolated from the tissues of one-day-old heads or the hypothalamus of adult
mice using a commercial kit (Trizol, Invitrogen). The total RNA was then reverse-transcribed
using the M-MuLV kit (Invitrogen), and the subsequent cDNA was used as a template for
quantitative real-time PCR. This analysis was performed with the iQ SYBR green supermix
(Bio-Rad) using the ViiA™ 7 Real-Time PCR System (Life Technologies). All qRT-PCR reac-
tions were carried out for 40 cycles under standard PCR conditions. The analyses of the results
from qRT-PCR were described previously [34]. Statistical significance of potential difference
of expression levels of a given gene between two samples was tested with Mann-Whitney U
test. The information regarding individual primer sequences is available through the previous
study [14, 17].
Immunohistochemistry
Each mouse was anesthetized with an intraperitoneal injection of a ketamine/xylazine cocktail
(87.5 mg/kg ketamine; 12.5 mg/kg xylazine) at a dosage of 0.1 ml per 20-gram body weight.
The animals were then transcardially perfused with 0.1 M sodium phosphate-buffered saline
(PBS: pH 7.2–7.4) and fixed with 4% paraformaldehyde in 0.1 M phosphate buffer (PB: pH
7.2–7.4). Mice were decapitated, and heads were post-fixed overnight in the same fixative.
Brains were dissected and blocked on either side of the hypothalamus. Coronal sections were
transected from the hypothalamus at 40 μm thickness using a vibratome (Leica VT1200 S,
Leica, Mannheim, Germany), and placed in PBS containing 0.5% Triton X-100 (PBST). The
free-floating brain sections were incubated with an in-house primary antibody against PEG3
[14] and the primary PS38 antibody against oxytocin-neurophysin (provided by H. Gainer,
NIH) at dilutions of 1:1000 and 1:500, respectively. This incubation was carried out in PBST
for 48–72 hours at 4˚C with continuous gentle agitation. Sections were washed three times
with fresh PBST, followed by incubation with goat anti-rabbit antibody conjugated with
DyLight 488 (Jackson ImmunoResearch, West Grove, PA) and DyLight 649 (Jackson Immu-
noResearch, West Grove, PA). Both incubations were performed at 1:400 dilution in PBST
overnight. The sections were washed three times with PBST, mounted on gelatin-coated slides,
dehydrated, cleared, and cover-slipped with an anti-fading agent that consists of 4.8g PVA,
12g glycerol, 12 mL dH2O, 24 mL 0.2M Tris-HCl, and 1.25g DABCO (1,4-diazabicyclo[2.2.2]
octane). Fluorescence images were acquired digitally (Eclipse 80i equipped with a digital cam-
era, DS-QiMc, Nikon, Tokyo, Japan). ImageJ software was used to process the images in
dynamic range with minimal alterations.
Supporting information
S1 File. This file contains the raw data from the breeding experiment, including transmis-
sion frequencies of each mutant group and weight data of individual mice, which have
been summarized as Fig 7.
(XLSX)
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